CD274 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), PD-L1 expression levels are used to stratify patients for treatment with pembrolizumab, where those with higher expression (≥50%) have shown better outcomes compared to chemotherapy [64,72,73].